Sutro Biopharma, Inc. (STRO) Stock Price & Analysis
Sutro Biopharma, Inc. (STRO) fell 3.05% to USD 22.88 as of July 25, 2026 at 04:59 UTC, according to Nexqual real-time market data.
STRO last closed at USD 23.6; the session ranged USD 21.72–23.72 on volume of 323,142 shares. Market capitalization is $379.13M, with a 52-week range of USD 7.15–43.85 (NGM). Source: Nexqual, July 25, 2026 at 04:59 UTC.
Key Statistics (as of July 25, 2026 at 04:59 UTC)
| Price | USD 22.88 |
|---|---|
| Change | ▼ 3.05% (down) |
| Previous Close | USD 23.6 |
| Open | USD 23.58 |
| Day Range | USD 21.72 – 23.72 |
| 52-Week Range | USD 7.15 – 43.85 |
| Volume | 323,142 shares |
| Market Cap | $379.13M |
| Exchange | NGM |
Technical Analysis (STRO)
Nexqual's technical model rates STRO "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:59 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.21 (neutral) |
| vs SMA50 | Below (USD 28.9) |
| MACD | -1.92 (negative) |
Analyst Ratings (STRO)
Wall Street analysts rate STRO "Strong Buy" based on 12 analysts, with a mean price target of USD 47.75 (range USD 10–61), per Nexqual as of July 25, 2026 at 04:59 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 47.75 |
| High Target | USD 61 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 11 / 0 / 1 |
Earnings (STRO)
| EPS Estimate | USD -2.39 |
|---|---|
| Revenue Estimate | $10.79M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.94 vs est -3.22 ▲ beat |
| 2025-12-31 | USD -4.88 vs est -4.43 ▼ miss |
| 2025-09-30 | USD -5.57 vs est -3.55 ▼ miss |
| 2025-06-30 | USD -1.4 vs est -5.3 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:59 UTC.
Financials & Fundamentals (STRO)
| Total Revenue | $99.61M |
|---|---|
| Revenue Growth (YoY) | -16.50% |
| Gross Margin | -51.97% |
| Operating Margin | -203.91% |
| Profit Margin | -154.21% |
| Current Ratio | 3.12 |
| Total Cash | $202.56M |
| Total Debt | $13.63M |
| Free Cash Flow | $-106.47M |
Source: Nexqual, July 25, 2026 at 04:59 UTC.
Financial Health Score (STRO)
Nexqual rates Sutro Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:59 UTC.
| Growth | Strong — Revenue +65% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $203M cash vs $14M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$106M, burning cash |
| Efficiency | Mixed — No data |
Ownership (STRO)
| Insider Ownership | +2.26% |
|---|---|
| Institutional Ownership | +88.19% |
| Shares Outstanding | 16.57M |
| Float | 10.30M |
| Short % of Float | +8.24% |
Source: Nexqual, July 25, 2026 at 04:59 UTC.
Leadership (STRO)
Sutro Biopharma, Inc. is led by Jane Chung R.Ph. (age 54), CEO & Director, per Nexqual as of July 25, 2026 at 04:59 UTC.
| CEO & Director | Jane Chung R.Ph. (age 54) |
|---|---|
| Chief Financial Officer | Gregory K. Chow BA (age 52) |
| Chief Scientific Officer | Hans-Peter Gerber (age 61) |
| Senior Vice President of Technical Operations | Devendra Luhar |
| Vice President & Controller | Regina Cheng |
Major Backers & Investors (STRO)
Notable institutional backers of Sutro Biopharma, Inc. include BVF Inc., Affinity Asset Advisors, Llc, Samsara BioCapital, LLC, according to Nexqual as of July 25, 2026 at 04:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BVF Inc. | 7.55% |
| Affinity Asset Advisors, Llc | 6.45% |
| Samsara BioCapital, LLC | 6.41% |
| Kynam Capital Management, LP | 5.27% |
| Orbimed Advisors LLC. | 4.83% |
| RA Capital Management, L.P. | 4.32% |
| Eventide Asset Management LLC | 4.32% |
| Perceptive Advisors Llc | 4.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.59% |
Source: Nexqual, July 25, 2026 at 04:59 UTC.
From Sutro Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Through December 31, 2025, we have received an aggregate of approximately $1.016 billion in payments from all of our collaborations, which includes approximately $79 million in investments in our stock.
- Our proprietary technology is key to our ability to define the best number and positions of non-natural amino acids for conjugation based on: conjugation efficiency; functional activity/pharmacological properties; and pharmacokinetics and safety.
- Through December 31, 2025, all of our collaborations have provided us with an aggregate of approximately $1.016 billion in payments, which includes approximately $79 million in investments in our stock.
- Overview We are a clinical stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF ® , and our site-specific conjugation platform, XpressCF+ ® .
Partnerships
- In 2024, we entered into an Exclusive License Agreement with Ipsen granting Ipsen worldwide rights to develop and commercialize STRO-003.
- To maximize the value of our XpressCF ® and XpressCF+ ® platform technology, we have historically entered into multitarget, product-focused collaborations with leaders in the field of oncology, including our iADC collaboration with Astellas.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | USD 29.3 | ▲ 1.17% |
| ALXO | ALX Oncology Holdings Inc. | USD 2.03 | ▲ 0.5% |
| SRRK | Scholar Rock Holding Corporatio | USD 47.67 | ▼ 1.3% |
| REPL | Replimune Group, Inc. | USD 9.7 | ▼ 9.77% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 4.33 | ▼ 3.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:59 UTC. This page is informational and not investment advice.